Stockreport

I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China

I-MAB - American Depositary Shares  (IMAB) 
PDF SHANGHAI, China, and ROCKVILLE, Md., and MUNICH, Germany, April 27, 2020 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed [Read more]